KI67-ANTIGEN EXPRESSION CORRELATES WITH TUMOR PROGRESSION AND HLA-DR ANTIGEN EXPRESSION IN MELANOCYTIC LESIONS

被引:39
作者
MORETTI, S [1 ]
MASSOBRIO, R [1 ]
BROGELLI, L [1 ]
NOVELLI, M [1 ]
GIANNOTTI, B [1 ]
BERNENGO, MG [1 ]
机构
[1] UNIV TURIN,DERMATOL CLIN 1,I-10124 TURIN,ITALY
关键词
D O I
10.1111/1523-1747.ep12485060
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Advanced steps of tumor progression are generally characterized by an increased growth fraction within the neoplastic cell population. The presence of a relevant growth fraction is also related to widely accepted prognostic parameters in some human malignancies. Our aims were to evaluate the presence of a growth fraction with Ki67 monoclonal antibody (MoAb), and to correlate it with tumor progression and HLA-DR antigen expression in 88 melanocytic lesions. The lesions were 19 acquired melanocytic nevi, 58 primary melanomas [divided into 26 superficial spreading melanomas (SSM), 24 superficial spreading melanomas with nodular areas (SS + NM), and five nodular melanomas (NM)], and 11 metastases from malignant melanomas. Ki67 MoAb stained 16%, 19%, 71%, 100%, and 82% of nevi, SSM, SS + NM NM, and metastases, respectively. Among primary melanomas, Ki67 MoAb stained 12%, 28%, 50%, and 70% of tumors < 0.75, 0.75-1.49, 1.5-2.9, and ≥ 3 mm thick, respectively. A concordant reactivity pattern for Ki67 and HLA-DR antigens was found in 72% of lesions (p < 0.0001). We have shown that a representative growth fraction (ie, Ki67 reactivity) is present in melanocytic lesions only in advanced steps of tumor progression and correlates with HLA-DR antigen expression. Despite the different biologic values of Ki67 and HLA-DR antigens, we suggest the joint evaluation of both antigens as a useful marker of aggressive behavior in melanoma. © 1990.
引用
收藏
页码:320 / 324
页数:5
相关论文
共 28 条
[1]   PROLIFERATIVE INDEX IN BREAST-CARCINOMA DETERMINED INSITU BY KI67 IMMUNOSTAINING AND ITS RELATIONSHIP TO CLINICAL AND PATHOLOGICAL VARIABLES [J].
BARNARD, NJ ;
HALL, PA ;
LEMOINE, NR ;
KADAR, N .
JOURNAL OF PATHOLOGY, 1987, 152 (04) :287-295
[3]   PHENOTYPIC DYNAMICS OF TUMOR PROGRESSION IN HUMAN-MALIGNANT MELANOMA [J].
BROCKER, EB ;
SUTER, L ;
BRUGGEN, J ;
RUITER, DJ ;
MACHER, E ;
SORG, C .
INTERNATIONAL JOURNAL OF CANCER, 1985, 36 (01) :29-35
[4]   HLA-DR ANTIGEN EXPRESSION IN PRIMARY MELANOMAS OF THE SKIN [J].
BROCKER, EB ;
SUTER, L ;
SORG, C .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1984, 82 (03) :244-247
[5]   THE BIOLOGIC FORMS OF MALIGNANT-MELANOMA [J].
CLARK, WH ;
ELDER, DE ;
VANHORN, M .
HUMAN PATHOLOGY, 1986, 17 (05) :443-450
[6]  
COSTA A, 1981, J NATL CANCER I, V66, P1
[7]  
COSTA A, 1987, CANCER-AM CANCER SOC, V60, P2797, DOI 10.1002/1097-0142(19871201)60:11<2797::AID-CNCR2820601133>3.0.CO
[8]  
2-B
[9]   GROWTH FRACTIONS IN BREAST CANCERS DETERMINED INSITU WITH MONOCLONAL-ANTIBODY KI-67 [J].
GERDES, J ;
LELLE, RJ ;
PICKARTZ, H ;
HEIDENREICH, W ;
SCHWARTING, R ;
KURTSIEFER, L ;
STAUCH, G ;
STEIN, H .
JOURNAL OF CLINICAL PATHOLOGY, 1986, 39 (09) :977-980
[10]  
Gerdes J, 1984, Hematol Oncol, V2, P365